News AZ's Tagrisso gets NHS funding in Scotland SMC backs drug based on feedback from patients and doctors, after rejection by NICE.
News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Janssen's Imbruvica recommended in CLL J&J unit awaiting decisions in two more blood cancer uses.
News Pharma criticises 'heavy handed' NICE affordability test NHS England and NICE are attempting to reduce budget impact of drugs.
News Myeloma drugs Darzalex and Kyprolis rejected in Scotland SMC says "no" to Amgen and Janssen multiple myeloma drugs.
News OECD calls for 'rebalancing of power' in drug price negotiat... Health systems should fund more treatments for chronic diseases, says EFPIA
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
